UPC Analytics
ENDE
Overview · Filed: —

CC_49716/2024

NOVEL ANTITUMORAL USE OF CABAZITAXEL

Parent infringement case:UPC_CFI_145/2024

RevocationCounter Claim for RevocationMunich LDCounterclaim for revocation—
OverviewDecisionsDocumentsTimeline
Parties

Claimants

  • Accord Healthcare S.L.U.
  • Accord Healthcare GmbH
  • Accord Healthcare B.V.
  • Accord Healthcare Italia Srl
  • Accord Healthcare AB
  • STADAPHARM GmbH
  • STADA Arzneimittel AG
  • STADA Nordic ApS
  • Reddy Pharma SAS
  • betapharm Arzneimittel GmbH
  • Dr Reddy's Srl
  • Zentiva France
  • Zentiva Pharma GmbH
  • Zentiva, k.s.
Reps: Frédéric Chevallier (Herbert Smith Freehills)

Respondents

Reps: Jules Fabre (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Judges
  • —
Patents
  • EP 2 493 466
CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16

Technology area: Pharmaceuticals · Oncology

Sector: Pharmaceutical & Medical

Outcome
Procedural onlyProcedural only (no substantive ruling yet)
Filed: —
First decided: Jan 24, 2025
Language: —